Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

LCTX holding history

Lineage Cell Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

LCTX overviewAll 13F holders of LCTXFull Q2 2026 holdings

Shares (Q2 2026)
687,051
Value
$900.0K
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of LCTX by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026687,051$900.0K<0.1%−683,410−49.9%ReducedHolders
Q1 20261,370,461$2.17M<0.1%+1,187,334+648.4%AddedHolders
Q4 2025183,127$305.8K<0.1%−24,953−12.0%ReducedHolders
Q3 2025208,080$351.7K<0.1%−19,520−8.6%ReducedHolders
Q2 2025227,600$206.4K<0.1%−36,317−13.8%ReducedHolders
Q1 2025263,917$119.3K<0.1%+43,029+19.5%AddedHolders
Q4 2024220,888$110.9K<0.1%+49,457+28.8%AddedHolders
Q3 2024171,431$155.1K<0.1%+94,965+124.2%AddedHolders
Q2 202476,466$76.2K<0.1%−63,606−45.4%ReducedHolders
Q1 2024140,072$207.3K<0.1%−4,455−3.1%ReducedHolders
Q4 2023144,527$157.5K<0.1%+91,556+172.8%AddedHolders
Q3 202352,971$62.5K<0.1%−8,066−13.2%ReducedHolders
Q2 202361,037$86.1K<0.1%+57,784+1,776.3%AddedHolders
Q1 20233,253$4.88K<0.1%−7,253−69.0%ReducedHolders
Q4 202210,506$12.3K<0.1%+9,204+706.9%AddedHolders
Q3 20221,302$1.00K<0.1%−10,118−88.6%ReducedHolders
Q2 202211,420$18.0K<0.1%+10,526+1,177.4%AddedHolders
Q1 2022894$1.00K<0.1%−39,038−97.8%ReducedHolders
Q4 202139,932$97.0K<0.1%−167,770−80.8%ReducedHolders
Q3 2021207,702$523.0K<0.1%+203,156+4,468.9%AddedHolders
Q2 20214,546$13.0K<0.1%−2,791−38.0%ReducedHolders
Q1 20217,337$17.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.